Listed in the December 27, 2023 extract; not in the current extract (September 22, 2026): Nat-Levetiracetam (02440202), Levetiracetam (02454653), Nat-Levetiracetam (02440210), Levetiracetam (02454661), Nat-Levetiracetam (02440229), Levetiracetam (02454688). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-09-22.xml.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Levetiracetam
Form:
24 of 24 products shown
All products: Limited Use (codes 473, 640, 705)
Mint-Levetiracetam Solution · DIN 02558416 · 100 mg/mL · Oral Sol
Limited Use, Reason for Use code 640, 705 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 640, 705 required
Write on scriptone applicable Reason for Use code, 640 or 705 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 640, 705
Reason for Use code 640
For patients unable to swallow or tolerate oral solid dosage forms and who are using this as adjunctive therapy in the treatment of seizure disorders where control by other listed anticonvulsants has been unsatisfactory.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 705
As adjunctive therapy in the treatment of seizure disorders in pediatric patients (less than 18 years of age) where control by other listed anticonvulsants has been unsatisfactory and where the appropriate dose cannot be achieved using listed solid oral levetiracetam dosage formats.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mint-Levetiracetam Solution · DIN 02558416
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2025-10-31
Health Canada: Marketed since 2025-08-14 · brand MINT-LEVETIRACETAM SOLUTION · ATC N03AX14 LEVETIRACETAM · form Solution · route Oral · ingredients LEVETIRACETAM 100 MG/ML · company Mint pharmaceuticals inc · schedule Prescription
Mint-Levetiracetam Solution: Formulary list price $0.41 per unit (the source does not state the unit; exact figure $0.4071). What the ministry pays, not the patient.
Ministry pays: $0.4071 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02558416: Mint-Levetiracetam Solution
Raw flags: sec12=Y, sec3=Y
Item: 281200183; group id 433; item number 1082; lccId 00365; manufacturer id MIN
Source form: Oral Sol; strength: 100mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.4071; ministry $0.4071
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02558416
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106166Interchangeable products
PDP-Levetiracetam · DIN 02490447 · $0.4071
Pharma-Levetiracetam · DIN 02515318 · $0.4071
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02558416
Shortage record checked October 6, 2026
PDP-Levetiracetam · DIN 02490447 · 100 mg/mL · Oral Sol
Limited Use, Reason for Use code 640, 705 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 640, 705 required
Write on scriptone applicable Reason for Use code, 640 or 705 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 640, 705
Reason for Use code 640
For patients unable to swallow or tolerate oral solid dosage forms and who are using this as adjunctive therapy in the treatment of seizure disorders where control by other listed anticonvulsants has been unsatisfactory.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 705
As adjunctive therapy in the treatment of seizure disorders in pediatric patients (less than 18 years of age) where control by other listed anticonvulsants has been unsatisfactory and where the appropriate dose cannot be achieved using listed solid oral levetiracetam dosage formats.
Coverage limit:
LU Authorization Period: 1 year
1 brand, same coverage
PDP-Levetiracetam · DIN 02490447
Manufacturer: Pendopharm, Division of Pharmascience Inc.; listing date 2022-12-21
Health Canada: Marketed since 2020-05-01 · brand PDP-LEVETIRACETAM · ATC N03AX14 LEVETIRACETAM · form Solution · route Oral · ingredients LEVETIRACETAM 100 MG/ML · company Pendopharm division of pharmascience inc · schedule Prescription
DIN 02490447: PDP-Levetiracetam
Raw flags: sec12=Y, sec3=Y
Item: 281200183; group id 433; item number 1082; lccId 00365; manufacturer id PEN
Source form: Oral Sol; strength: 100mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.8142; ministry $0.4071
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02490447
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98049Interchangeable products
Mint-Levetiracetam Solution · DIN 02558416 · $0.4071
Pharma-Levetiracetam · DIN 02515318 · $0.4071
Shortage status: resolved shortage (ended April 21, 2021); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02490447
Shortage record checked October 6, 2026
Pharma-Levetiracetam · DIN 02515318 · 100 mg/mL · Oral Sol
Limited Use, Reason for Use code 640, 705 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 640, 705 required
Write on scriptone applicable Reason for Use code, 640 or 705 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 640, 705
Reason for Use code 640
For patients unable to swallow or tolerate oral solid dosage forms and who are using this as adjunctive therapy in the treatment of seizure disorders where control by other listed anticonvulsants has been unsatisfactory.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 705
As adjunctive therapy in the treatment of seizure disorders in pediatric patients (less than 18 years of age) where control by other listed anticonvulsants has been unsatisfactory and where the appropriate dose cannot be achieved using listed solid oral levetiracetam dosage formats.
Coverage limit:
LU Authorization Period: 1 year
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Pharma-Levetiracetam · DIN 02515318
Manufacturer: Pharmascience Inc.; listing date 2025-12-30
Health Canada: Marketed since 2025-12-22 · brand PHARMA-LEVETIRACETAM · ATC N03AX14 LEVETIRACETAM · form Solution · route Oral · ingredients LEVETIRACETAM 100 MG/ML · company Pharmascience inc · schedule Prescription
Pharma-Levetiracetam: Formulary list price $0.41 per unit (the source does not state the unit; exact figure $0.4071). What the ministry pays, not the patient.
Ministry pays: $0.4071 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02515318: Pharma-Levetiracetam
Raw flags: sec12=Y, sec3=Y
Item: 281200183; group id 433; item number 1082; lccId 00365; manufacturer id PMS
Source form: Oral Sol; strength: 100mg/mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.4071; ministry $0.4071
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02515318
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100470Interchangeable products
Mint-Levetiracetam Solution · DIN 02558416 · $0.4071
PDP-Levetiracetam · DIN 02490447 · $0.4071
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02515318
Shortage record checked October 6, 2026
Act Levetiracetam · DIN 02274183 · 250 mg · tablet
Limited Use, Reason for Use code 473 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 473 required
Write on scriptReason for Use code 473 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 473
Reason for Use code 473
As adjunctive therapy in the treatment of seizure disorders where control by other listed anticonvulsants has been unsatisfactory.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Act Levetiracetam · DIN 02274183
Manufacturer: Actavis Pharma Company; listing date 2007-12-19
Health Canada: Marketed since 2020-12-17 · brand TEVA-LEVETIRACETAM · ATC N03AX14 LEVETIRACETAM · form Tablet · route Oral · ingredients LEVETIRACETAM 250 MG · company Teva canada limited · schedule Prescription
Act Levetiracetam: Formulary list price $0.32 per unit (the source does not state the unit; exact figure $0.3210). What the ministry pays, not the patient.
Ministry pays: $0.3210 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02274183: Act Levetiracetam
Raw flags: sec12=Y, sec3=Y
Item: 281200091; group id 434; item number 1083; lccId 00266; manufacturer id ACV
Source form: Tab; strength: 250mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.3210; ministry $0.3210
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02274183
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75964Interchangeable products
Ach-Levetiracetam · DIN 02399776 · $0.3210
Apo-Levetiracetam · DIN 02285924 · $0.3210
Auro-Levetiracetam · DIN 02375249 · $0.3210
Jamp Levetiracetam Tablets · DIN 02504553 · $0.3210
Jamp-Levetiracetam · DIN 02403005 · $0.3210
Keppra · DIN 02247027 · $0.3210
Levetiracetam · DIN 02353342 · $0.3210
Levetiracetam · DIN 02442531 · $0.3210
M-Levetiracetam · DIN 02524562 · $0.3210
Mint-Levetiracetam · DIN 02442388 · $0.3210
NRA-Levetiracetam · DIN 02499193 · $0.3210
PMS-Levetiracetam · DIN 02296101 · $0.3210
Riva-Levetiracetam · DIN 02482274 · $0.3210
Sandoz Levetiracetam · DIN 02461986 · $0.3210
Shortage status: resolved shortage (ended January 28, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02274183
Shortage record checked October 6, 2026
Apo-Levetiracetam · DIN 02285924 · 250 mg · tablet
Limited Use, Reason for Use code 473 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 473 required
Write on scriptReason for Use code 473 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 473
Reason for Use code 473
As adjunctive therapy in the treatment of seizure disorders where control by other listed anticonvulsants has been unsatisfactory.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Levetiracetam · DIN 02285924
Manufacturer: Apotex Inc.; listing date 2007-11-10
Health Canada: Marketed since 2006-10-20 · brand APO-LEVETIRACETAM · ATC N03AX14 LEVETIRACETAM · form Tablet · route Oral · ingredients LEVETIRACETAM 250 MG · company Apotex inc · schedule Prescription
Apo-Levetiracetam: Formulary list price $0.32 per unit (the source does not state the unit; exact figure $0.3210). What the ministry pays, not the patient.
Ministry pays: $0.3210 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02285924: Apo-Levetiracetam
Raw flags: sec12=Y, sec3=Y
Item: 281200091; group id 434; item number 1083; lccId 00266; manufacturer id APX
Source form: Tab; strength: 250mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.3210; ministry $0.3210
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02285924
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77141Interchangeable products
Ach-Levetiracetam · DIN 02399776 · $0.3210
Act Levetiracetam · DIN 02274183 · $0.3210
Auro-Levetiracetam · DIN 02375249 · $0.3210
Jamp Levetiracetam Tablets · DIN 02504553 · $0.3210
Jamp-Levetiracetam · DIN 02403005 · $0.3210
Keppra · DIN 02247027 · $0.3210
Levetiracetam · DIN 02353342 · $0.3210
Levetiracetam · DIN 02442531 · $0.3210
M-Levetiracetam · DIN 02524562 · $0.3210
Mint-Levetiracetam · DIN 02442388 · $0.3210
NRA-Levetiracetam · DIN 02499193 · $0.3210
PMS-Levetiracetam · DIN 02296101 · $0.3210
Riva-Levetiracetam · DIN 02482274 · $0.3210
Sandoz Levetiracetam · DIN 02461986 · $0.3210
Shortage status: resolved shortage (ended September 3, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02285924
Shortage record checked October 6, 2026
Auro-Levetiracetam · DIN 02375249 · 250 mg · tablet
Limited Use, Reason for Use code 473 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 473 required
Write on scriptReason for Use code 473 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 473
Reason for Use code 473
As adjunctive therapy in the treatment of seizure disorders where control by other listed anticonvulsants has been unsatisfactory.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Levetiracetam · DIN 02375249
Manufacturer: Auro Pharma Inc.; listing date 2012-04-24
Health Canada: Marketed since 2012-02-14 · brand AURO-LEVETIRACETAM · ATC N03AX14 LEVETIRACETAM · form Tablet · route Oral · ingredients LEVETIRACETAM 250 MG · company Auro pharma inc · schedule Prescription
Auro-Levetiracetam: Formulary list price $0.32 per unit (the source does not state the unit; exact figure $0.3210). What the ministry pays, not the patient.
Ministry pays: $0.3210 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02375249: Auro-Levetiracetam
Raw flags: sec12=Y, sec3=Y
Item: 281200091; group id 434; item number 1083; lccId 00266; manufacturer id AUR
Source form: Tab; strength: 250mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.3210; ministry $0.3210
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02375249
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86064Interchangeable products
Ach-Levetiracetam · DIN 02399776 · $0.3210
Act Levetiracetam · DIN 02274183 · $0.3210
Apo-Levetiracetam · DIN 02285924 · $0.3210
Jamp Levetiracetam Tablets · DIN 02504553 · $0.3210
Jamp-Levetiracetam · DIN 02403005 · $0.3210
Keppra · DIN 02247027 · $0.3210
Levetiracetam · DIN 02353342 · $0.3210
Levetiracetam · DIN 02442531 · $0.3210
M-Levetiracetam · DIN 02524562 · $0.3210
Mint-Levetiracetam · DIN 02442388 · $0.3210
NRA-Levetiracetam · DIN 02499193 · $0.3210
PMS-Levetiracetam · DIN 02296101 · $0.3210
Riva-Levetiracetam · DIN 02482274 · $0.3210
Sandoz Levetiracetam · DIN 02461986 · $0.3210
Shortage status: resolved shortage (ended March 15, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02375249
Limited Use, Reason for Use code 473 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 473 required
Write on scriptReason for Use code 473 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 473
Reason for Use code 473
As adjunctive therapy in the treatment of seizure disorders where control by other listed anticonvulsants has been unsatisfactory.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Levetiracetam Tablets · DIN 02504553
Manufacturer: Jamp Pharma Corporation; listing date 2022-08-31
Health Canada: Marketed since 2022-06-10 · brand JAMP LEVETIRACETAM TABLETS · ATC N03AX14 LEVETIRACETAM · form Tablet · route Oral · ingredients LEVETIRACETAM 250 MG · company Jamp pharma corporation · schedule Prescription
Jamp Levetiracetam Tablets: Formulary list price $0.32 per unit (the source does not state the unit; exact figure $0.3210). What the ministry pays, not the patient.
Ministry pays: $0.3210 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02504553: Jamp Levetiracetam Tablets
Raw flags: sec12=Y, sec3=Y
Item: 281200091; group id 434; item number 1083; lccId 00266; manufacturer id JPC
Source form: Tab; strength: 250mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.3210; ministry $0.3210
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02504553
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99397Interchangeable products
Ach-Levetiracetam · DIN 02399776 · $0.3210
Act Levetiracetam · DIN 02274183 · $0.3210
Apo-Levetiracetam · DIN 02285924 · $0.3210
Auro-Levetiracetam · DIN 02375249 · $0.3210
Jamp-Levetiracetam · DIN 02403005 · $0.3210
Keppra · DIN 02247027 · $0.3210
Levetiracetam · DIN 02353342 · $0.3210
Levetiracetam · DIN 02442531 · $0.3210
M-Levetiracetam · DIN 02524562 · $0.3210
Mint-Levetiracetam · DIN 02442388 · $0.3210
NRA-Levetiracetam · DIN 02499193 · $0.3210
PMS-Levetiracetam · DIN 02296101 · $0.3210
Riva-Levetiracetam · DIN 02482274 · $0.3210
Sandoz Levetiracetam · DIN 02461986 · $0.3210
Shortage status: resolved shortage (ended December 20, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02504553
Shortage record checked October 6, 2026
Keppra · DIN 02247027 · 250 mg · tablet
Limited Use, Reason for Use code 473 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 473 required
Write on scriptReason for Use code 473 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 473
Reason for Use code 473
As adjunctive therapy in the treatment of seizure disorders where control by other listed anticonvulsants has been unsatisfactory.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Keppra · DIN 02247027
Manufacturer: UCB Canada Inc.; listing date 2007-11-10
Health Canada: Marketed since 2010-09-10 · brand KEPPRA · ATC N03AX14 LEVETIRACETAM · form Tablet · route Oral · ingredients LEVETIRACETAM 250 MG · company Ucb canada inc · schedule Prescription
DIN 02247027: Keppra
Raw flags: sec12=Y, sec3=Y
Item: 281200091; group id 434; item number 1083; lccId 00266; manufacturer id UCB
Source form: Tab; strength: 250mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.7836; ministry $0.3210
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02247027
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71262Interchangeable products
Ach-Levetiracetam · DIN 02399776 · $0.3210
Act Levetiracetam · DIN 02274183 · $0.3210
Apo-Levetiracetam · DIN 02285924 · $0.3210
Auro-Levetiracetam · DIN 02375249 · $0.3210
Jamp Levetiracetam Tablets · DIN 02504553 · $0.3210
Jamp-Levetiracetam · DIN 02403005 · $0.3210
Levetiracetam · DIN 02353342 · $0.3210
Levetiracetam · DIN 02442531 · $0.3210
M-Levetiracetam · DIN 02524562 · $0.3210
Mint-Levetiracetam · DIN 02442388 · $0.3210
NRA-Levetiracetam · DIN 02499193 · $0.3210
PMS-Levetiracetam · DIN 02296101 · $0.3210
Riva-Levetiracetam · DIN 02482274 · $0.3210
Sandoz Levetiracetam · DIN 02461986 · $0.3210
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02247027
Shortage record checked October 6, 2026
Levetiracetam · DIN 02353342 · 250 mg · tablet
Limited Use, Reason for Use code 473 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 473 required
Write on scriptReason for Use code 473 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 473
Reason for Use code 473
As adjunctive therapy in the treatment of seizure disorders where control by other listed anticonvulsants has been unsatisfactory.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Levetiracetam · DIN 02353342
Manufacturer: Sanis Health Inc.; listing date 2011-08-04
Health Canada: Marketed since 2023-07-04 · brand LEVETIRACETAM · ATC N03AX14 LEVETIRACETAM · form Tablet · route Oral · ingredients LEVETIRACETAM 250 MG · company Sanis health inc · schedule Prescription
Levetiracetam: Formulary list price $0.32 per unit (the source does not state the unit; exact figure $0.3210). What the ministry pays, not the patient.
Ministry pays: $0.3210 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02353342: Levetiracetam
Raw flags: sec12=Y, sec3=Y
Item: 281200091; group id 434; item number 1083; lccId 00266; manufacturer id SAI
Source form: Tab; strength: 250mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.3210; ministry $0.3210
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02353342
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83854Interchangeable products
Ach-Levetiracetam · DIN 02399776 · $0.3210
Act Levetiracetam · DIN 02274183 · $0.3210
Apo-Levetiracetam · DIN 02285924 · $0.3210
Auro-Levetiracetam · DIN 02375249 · $0.3210
Jamp Levetiracetam Tablets · DIN 02504553 · $0.3210
Jamp-Levetiracetam · DIN 02403005 · $0.3210
Keppra · DIN 02247027 · $0.3210
Levetiracetam · DIN 02442531 · $0.3210
M-Levetiracetam · DIN 02524562 · $0.3210
Mint-Levetiracetam · DIN 02442388 · $0.3210
NRA-Levetiracetam · DIN 02499193 · $0.3210
PMS-Levetiracetam · DIN 02296101 · $0.3210
Riva-Levetiracetam · DIN 02482274 · $0.3210
Sandoz Levetiracetam · DIN 02461986 · $0.3210
Shortage status: resolved shortage (ended March 1, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02353342
Shortage record checked October 6, 2026
Levetiracetam · DIN 02442531 · 250 mg · tablet
Limited Use, Reason for Use code 473 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 473 required
Write on scriptReason for Use code 473 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 473
Reason for Use code 473
As adjunctive therapy in the treatment of seizure disorders where control by other listed anticonvulsants has been unsatisfactory.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Levetiracetam · DIN 02442531
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-08-28
Health Canada: Marketed since 2018-04-13 · brand LEVETIRACETAM · ATC N03AX14 LEVETIRACETAM · form Tablet · route Oral · ingredients LEVETIRACETAM 250 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Levetiracetam: Formulary list price $0.32 per unit (the source does not state the unit; exact figure $0.3210). What the ministry pays, not the patient.
Ministry pays: $0.3210 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02442531: Levetiracetam
Raw flags: sec12=Y, sec3=Y
Item: 281200091; group id 434; item number 1083; lccId 00266; manufacturer id SIV
Source form: Tab; strength: 250mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.3210; ministry $0.3210
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02442531
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92688Interchangeable products
Ach-Levetiracetam · DIN 02399776 · $0.3210
Act Levetiracetam · DIN 02274183 · $0.3210
Apo-Levetiracetam · DIN 02285924 · $0.3210
Auro-Levetiracetam · DIN 02375249 · $0.3210
Jamp Levetiracetam Tablets · DIN 02504553 · $0.3210
Jamp-Levetiracetam · DIN 02403005 · $0.3210
Keppra · DIN 02247027 · $0.3210
Levetiracetam · DIN 02353342 · $0.3210
M-Levetiracetam · DIN 02524562 · $0.3210
Mint-Levetiracetam · DIN 02442388 · $0.3210
NRA-Levetiracetam · DIN 02499193 · $0.3210
PMS-Levetiracetam · DIN 02296101 · $0.3210
Riva-Levetiracetam · DIN 02482274 · $0.3210
Sandoz Levetiracetam · DIN 02461986 · $0.3210
Shortage status: resolved shortage (ended April 27, 2018); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02442531
Shortage record checked October 6, 2026
Mint-Levetiracetam · DIN 02442388 · 250 mg · tablet
Limited Use, Reason for Use code 473 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 473 required
Write on scriptReason for Use code 473 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 473
Reason for Use code 473
As adjunctive therapy in the treatment of seizure disorders where control by other listed anticonvulsants has been unsatisfactory.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mint-Levetiracetam · DIN 02442388
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2021-11-30
Health Canada: Marketed since 2021-06-28 · brand MINT-LEVETIRACETAM · ATC N03AX14 LEVETIRACETAM · form Tablet · route Oral · ingredients LEVETIRACETAM 250 MG · company Mint pharmaceuticals inc · schedule Prescription
Mint-Levetiracetam: Formulary list price $0.32 per unit (the source does not state the unit; exact figure $0.3210). What the ministry pays, not the patient.
Ministry pays: $0.3210 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02442388: Mint-Levetiracetam
Raw flags: sec12=Y, sec3=Y
Item: 281200091; group id 434; item number 1083; lccId 00266; manufacturer id MIN
Source form: Tab; strength: 250mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.3210; ministry $0.3210
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02442388
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92674Interchangeable products
Ach-Levetiracetam · DIN 02399776 · $0.3210
Act Levetiracetam · DIN 02274183 · $0.3210
Apo-Levetiracetam · DIN 02285924 · $0.3210
Auro-Levetiracetam · DIN 02375249 · $0.3210
Jamp Levetiracetam Tablets · DIN 02504553 · $0.3210
Jamp-Levetiracetam · DIN 02403005 · $0.3210
Keppra · DIN 02247027 · $0.3210
Levetiracetam · DIN 02353342 · $0.3210
Levetiracetam · DIN 02442531 · $0.3210
M-Levetiracetam · DIN 02524562 · $0.3210
NRA-Levetiracetam · DIN 02499193 · $0.3210
PMS-Levetiracetam · DIN 02296101 · $0.3210
Riva-Levetiracetam · DIN 02482274 · $0.3210
Sandoz Levetiracetam · DIN 02461986 · $0.3210
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02442388
Shortage record checked October 6, 2026
NRA-Levetiracetam · DIN 02499193 · 250 mg · tablet
Limited Use, Reason for Use code 473 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 473 required
Write on scriptReason for Use code 473 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 473
Reason for Use code 473
As adjunctive therapy in the treatment of seizure disorders where control by other listed anticonvulsants has been unsatisfactory.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
NRA-Levetiracetam · DIN 02499193
Manufacturer: Nora Pharma; listing date 2021-05-31
Health Canada: Marketed since 2021-02-17 · brand NRA-LEVETIRACETAM · ATC N03AX14 LEVETIRACETAM · form Tablet · route Oral · ingredients LEVETIRACETAM 250 MG · company Nora pharma inc · schedule Prescription
NRA-Levetiracetam: Formulary list price $0.32 per unit (the source does not state the unit; exact figure $0.3210). What the ministry pays, not the patient.
Ministry pays: $0.3210 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02499193: NRA-Levetiracetam
Raw flags: sec12=Y, sec3=Y
Item: 281200091; group id 434; item number 1083; lccId 00266; manufacturer id NRA
Source form: Tab; strength: 250mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.3210; ministry $0.3210
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02499193
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98894Interchangeable products
Ach-Levetiracetam · DIN 02399776 · $0.3210
Act Levetiracetam · DIN 02274183 · $0.3210
Apo-Levetiracetam · DIN 02285924 · $0.3210
Auro-Levetiracetam · DIN 02375249 · $0.3210
Jamp Levetiracetam Tablets · DIN 02504553 · $0.3210
Jamp-Levetiracetam · DIN 02403005 · $0.3210
Keppra · DIN 02247027 · $0.3210
Levetiracetam · DIN 02353342 · $0.3210
Levetiracetam · DIN 02442531 · $0.3210
M-Levetiracetam · DIN 02524562 · $0.3210
Mint-Levetiracetam · DIN 02442388 · $0.3210
PMS-Levetiracetam · DIN 02296101 · $0.3210
Riva-Levetiracetam · DIN 02482274 · $0.3210
Sandoz Levetiracetam · DIN 02461986 · $0.3210
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02499193
Shortage record checked October 6, 2026
PMS-Levetiracetam · DIN 02296101 · 250 mg · tablet
Limited Use, Reason for Use code 473 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 473 required
Write on scriptReason for Use code 473 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 473
Reason for Use code 473
As adjunctive therapy in the treatment of seizure disorders where control by other listed anticonvulsants has been unsatisfactory.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Levetiracetam · DIN 02296101
Manufacturer: Pharmascience Inc.; listing date 2007-11-10
Health Canada: Marketed since 2021-09-30 · brand PMS-LEVETIRACETAM · ATC N03AX14 LEVETIRACETAM · form Tablet · route Oral · ingredients LEVETIRACETAM 250 MG · company Pharmascience inc · schedule Prescription
PMS-Levetiracetam: Formulary list price $0.32 per unit (the source does not state the unit; exact figure $0.3210). What the ministry pays, not the patient.
Ministry pays: $0.3210 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02296101: PMS-Levetiracetam
Raw flags: sec12=Y, sec3=Y
Item: 281200091; group id 434; item number 1083; lccId 00266; manufacturer id PMS
Source form: Tab; strength: 250mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.3210; ministry $0.3210
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02296101
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78145Interchangeable products
Ach-Levetiracetam · DIN 02399776 · $0.3210
Act Levetiracetam · DIN 02274183 · $0.3210
Apo-Levetiracetam · DIN 02285924 · $0.3210
Auro-Levetiracetam · DIN 02375249 · $0.3210
Jamp Levetiracetam Tablets · DIN 02504553 · $0.3210
Jamp-Levetiracetam · DIN 02403005 · $0.3210
Keppra · DIN 02247027 · $0.3210
Levetiracetam · DIN 02353342 · $0.3210
Levetiracetam · DIN 02442531 · $0.3210
M-Levetiracetam · DIN 02524562 · $0.3210
Mint-Levetiracetam · DIN 02442388 · $0.3210
NRA-Levetiracetam · DIN 02499193 · $0.3210
Riva-Levetiracetam · DIN 02482274 · $0.3210
Sandoz Levetiracetam · DIN 02461986 · $0.3210
Shortage status: resolved shortage (ended May 31, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02296101
Shortage record checked October 6, 2026
Sandoz Levetiracetam · DIN 02461986 · 250 mg · tablet
Limited Use, Reason for Use code 473 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 473 required
Write on scriptReason for Use code 473 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 473
Reason for Use code 473
As adjunctive therapy in the treatment of seizure disorders where control by other listed anticonvulsants has been unsatisfactory.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Levetiracetam · DIN 02461986
Manufacturer: Sandoz Canada Inc.; listing date 2017-09-28
Health Canada: Marketed since 2017-08-04 · brand SANDOZ LEVETIRACETAM · ATC N03AX14 LEVETIRACETAM · form Tablet · route Oral · ingredients LEVETIRACETAM 250 MG · company Sandoz canada incorporated · schedule Prescription
Sandoz Levetiracetam: Formulary list price $0.32 per unit (the source does not state the unit; exact figure $0.3210). What the ministry pays, not the patient.
Ministry pays: $0.3210 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02461986: Sandoz Levetiracetam
Raw flags: sec12=Y, sec3=Y
Item: 281200091; group id 434; item number 1083; lccId 00266; manufacturer id SDZ
Source form: Tab; strength: 250mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.3210; ministry $0.3210
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02461986
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94973Interchangeable products
Ach-Levetiracetam · DIN 02399776 · $0.3210
Act Levetiracetam · DIN 02274183 · $0.3210
Apo-Levetiracetam · DIN 02285924 · $0.3210
Auro-Levetiracetam · DIN 02375249 · $0.3210
Jamp Levetiracetam Tablets · DIN 02504553 · $0.3210
Jamp-Levetiracetam · DIN 02403005 · $0.3210
Keppra · DIN 02247027 · $0.3210
Levetiracetam · DIN 02353342 · $0.3210
Levetiracetam · DIN 02442531 · $0.3210
M-Levetiracetam · DIN 02524562 · $0.3210
Mint-Levetiracetam · DIN 02442388 · $0.3210
NRA-Levetiracetam · DIN 02499193 · $0.3210
PMS-Levetiracetam · DIN 02296101 · $0.3210
Riva-Levetiracetam · DIN 02482274 · $0.3210
Shortage status: resolved shortage (ended March 20, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02461986
Shortage record checked October 6, 2026
Act Levetiracetam · DIN 02274191 · 500 mg · tablet
Limited Use, Reason for Use code 473 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 473 required
Write on scriptReason for Use code 473 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 473
Reason for Use code 473
As adjunctive therapy in the treatment of seizure disorders where control by other listed anticonvulsants has been unsatisfactory.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Act Levetiracetam · DIN 02274191
Manufacturer: Actavis Pharma Company; listing date 2007-12-19
Health Canada: Marketed since 2020-12-17 · brand TEVA-LEVETIRACETAM · ATC N03AX14 LEVETIRACETAM · form Tablet · route Oral · ingredients LEVETIRACETAM 500 MG · company Teva canada limited · schedule Prescription
Act Levetiracetam: Formulary list price $0.39 per unit (the source does not state the unit; exact figure $0.3911). What the ministry pays, not the patient.
Ministry pays: $0.3911 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02274191: Act Levetiracetam
Raw flags: sec12=Y, sec3=Y
Item: 281200092; group id 434; item number 1084; lccId 00266; manufacturer id ACV
Source form: Tab; strength: 500mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.3911; ministry $0.3911
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02274191
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75965Interchangeable products
Ach-Levetiracetam · DIN 02399784 · $0.3911
Apo-Levetiracetam · DIN 02285932 · $0.3911
Auro-Levetiracetam · DIN 02375257 · $0.3911
Jamp Levetiracetam Tablets · DIN 02504561 · $0.3911
Jamp-Levetiracetam · DIN 02403021 · $0.3911
Keppra · DIN 02247028 · $0.3911
Levetiracetam · DIN 02353350 · $0.3911
Levetiracetam · DIN 02442558 · $0.3911
M-Levetiracetam · DIN 02524570 · $0.3911
Mint-Levetiracetam · DIN 02442396 · $0.3911
NRA-Levetiracetam · DIN 02499207 · $0.3911
PMS-Levetiracetam · DIN 02296128 · $0.3911
Riva-Levetiracetam · DIN 02482282 · $0.3911
Sandoz Levetiracetam · DIN 02461994 · $0.3911
Shortage status: resolved shortage (ended December 17, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02274191
Shortage record checked October 6, 2026
Apo-Levetiracetam · DIN 02285932 · 500 mg · tablet
Limited Use, Reason for Use code 473 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 473 required
Write on scriptReason for Use code 473 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 473
Reason for Use code 473
As adjunctive therapy in the treatment of seizure disorders where control by other listed anticonvulsants has been unsatisfactory.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Levetiracetam · DIN 02285932
Manufacturer: Apotex Inc.; listing date 2007-11-10
Health Canada: Marketed since 2006-10-20 · brand APO-LEVETIRACETAM · ATC N03AX14 LEVETIRACETAM · form Tablet · route Oral · ingredients LEVETIRACETAM 500 MG · company Apotex inc · schedule Prescription
Apo-Levetiracetam: Formulary list price $0.39 per unit (the source does not state the unit; exact figure $0.3911). What the ministry pays, not the patient.
Ministry pays: $0.3911 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02285932: Apo-Levetiracetam
Raw flags: sec12=Y, sec3=Y
Item: 281200092; group id 434; item number 1084; lccId 00266; manufacturer id APX
Source form: Tab; strength: 500mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.3911; ministry $0.3911
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02285932
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77142Interchangeable products
Ach-Levetiracetam · DIN 02399784 · $0.3911
Act Levetiracetam · DIN 02274191 · $0.3911
Auro-Levetiracetam · DIN 02375257 · $0.3911
Jamp Levetiracetam Tablets · DIN 02504561 · $0.3911
Jamp-Levetiracetam · DIN 02403021 · $0.3911
Keppra · DIN 02247028 · $0.3911
Levetiracetam · DIN 02353350 · $0.3911
Levetiracetam · DIN 02442558 · $0.3911
M-Levetiracetam · DIN 02524570 · $0.3911
Mint-Levetiracetam · DIN 02442396 · $0.3911
NRA-Levetiracetam · DIN 02499207 · $0.3911
PMS-Levetiracetam · DIN 02296128 · $0.3911
Riva-Levetiracetam · DIN 02482282 · $0.3911
Sandoz Levetiracetam · DIN 02461994 · $0.3911
Shortage status: resolved shortage (ended September 3, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02285932
Shortage record checked October 6, 2026
Auro-Levetiracetam · DIN 02375257 · 500 mg · tablet
Limited Use, Reason for Use code 473 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 473 required
Write on scriptReason for Use code 473 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 473
Reason for Use code 473
As adjunctive therapy in the treatment of seizure disorders where control by other listed anticonvulsants has been unsatisfactory.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Levetiracetam · DIN 02375257
Manufacturer: Auro Pharma Inc.; listing date 2012-04-24
Health Canada: Marketed since 2012-03-15 · brand AURO-LEVETIRACETAM · ATC N03AX14 LEVETIRACETAM · form Tablet · route Oral · ingredients LEVETIRACETAM 500 MG · company Auro pharma inc · schedule Prescription
Auro-Levetiracetam: Formulary list price $0.39 per unit (the source does not state the unit; exact figure $0.3911). What the ministry pays, not the patient.
Ministry pays: $0.3911 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02375257: Auro-Levetiracetam
Raw flags: sec12=Y, sec3=Y
Item: 281200092; group id 434; item number 1084; lccId 00266; manufacturer id AUR
Source form: Tab; strength: 500mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.3911; ministry $0.3911
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02375257
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86065Interchangeable products
Ach-Levetiracetam · DIN 02399784 · $0.3911
Act Levetiracetam · DIN 02274191 · $0.3911
Apo-Levetiracetam · DIN 02285932 · $0.3911
Jamp Levetiracetam Tablets · DIN 02504561 · $0.3911
Jamp-Levetiracetam · DIN 02403021 · $0.3911
Keppra · DIN 02247028 · $0.3911
Levetiracetam · DIN 02353350 · $0.3911
Levetiracetam · DIN 02442558 · $0.3911
M-Levetiracetam · DIN 02524570 · $0.3911
Mint-Levetiracetam · DIN 02442396 · $0.3911
NRA-Levetiracetam · DIN 02499207 · $0.3911
PMS-Levetiracetam · DIN 02296128 · $0.3911
Riva-Levetiracetam · DIN 02482282 · $0.3911
Sandoz Levetiracetam · DIN 02461994 · $0.3911
Shortage status: resolved shortage (ended January 9, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02375257
Limited Use, Reason for Use code 473 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 473 required
Write on scriptReason for Use code 473 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 473
Reason for Use code 473
As adjunctive therapy in the treatment of seizure disorders where control by other listed anticonvulsants has been unsatisfactory.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Levetiracetam Tablets · DIN 02504561
Manufacturer: Jamp Pharma Corporation; listing date 2022-08-31
Health Canada: Marketed since 2022-06-10 · brand JAMP LEVETIRACETAM TABLETS · ATC N03AX14 LEVETIRACETAM · form Tablet · route Oral · ingredients LEVETIRACETAM 500 MG · company Jamp pharma corporation · schedule Prescription
Jamp Levetiracetam Tablets: Formulary list price $0.39 per unit (the source does not state the unit; exact figure $0.3911). What the ministry pays, not the patient.
Ministry pays: $0.3911 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02504561: Jamp Levetiracetam Tablets
Raw flags: sec12=Y, sec3=Y
Item: 281200092; group id 434; item number 1084; lccId 00266; manufacturer id JPC
Source form: Tab; strength: 500mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.3911; ministry $0.3911
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02504561
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99398Interchangeable products
Ach-Levetiracetam · DIN 02399784 · $0.3911
Act Levetiracetam · DIN 02274191 · $0.3911
Apo-Levetiracetam · DIN 02285932 · $0.3911
Auro-Levetiracetam · DIN 02375257 · $0.3911
Jamp-Levetiracetam · DIN 02403021 · $0.3911
Keppra · DIN 02247028 · $0.3911
Levetiracetam · DIN 02353350 · $0.3911
Levetiracetam · DIN 02442558 · $0.3911
M-Levetiracetam · DIN 02524570 · $0.3911
Mint-Levetiracetam · DIN 02442396 · $0.3911
NRA-Levetiracetam · DIN 02499207 · $0.3911
PMS-Levetiracetam · DIN 02296128 · $0.3911
Riva-Levetiracetam · DIN 02482282 · $0.3911
Sandoz Levetiracetam · DIN 02461994 · $0.3911
Shortage status: resolved shortage (ended December 20, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02504561
Shortage record checked October 6, 2026
Keppra · DIN 02247028 · 500 mg · tablet
Limited Use, Reason for Use code 473 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 473 required
Write on scriptReason for Use code 473 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 473
Reason for Use code 473
As adjunctive therapy in the treatment of seizure disorders where control by other listed anticonvulsants has been unsatisfactory.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Keppra · DIN 02247028
Manufacturer: UCB Canada Inc.; listing date 2007-11-10
Health Canada: Marketed since 2010-09-13 · brand KEPPRA · ATC N03AX14 LEVETIRACETAM · form Tablet · route Oral · ingredients LEVETIRACETAM 500 MG · company Ucb canada inc · schedule Prescription
DIN 02247028: Keppra
Raw flags: sec12=Y, sec3=Y
Item: 281200092; group id 434; item number 1084; lccId 00266; manufacturer id UCB
Source form: Tab; strength: 500mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $2.1725; ministry $0.3911
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02247028
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71263Interchangeable products
Ach-Levetiracetam · DIN 02399784 · $0.3911
Act Levetiracetam · DIN 02274191 · $0.3911
Apo-Levetiracetam · DIN 02285932 · $0.3911
Auro-Levetiracetam · DIN 02375257 · $0.3911
Jamp Levetiracetam Tablets · DIN 02504561 · $0.3911
Jamp-Levetiracetam · DIN 02403021 · $0.3911
Levetiracetam · DIN 02353350 · $0.3911
Levetiracetam · DIN 02442558 · $0.3911
M-Levetiracetam · DIN 02524570 · $0.3911
Mint-Levetiracetam · DIN 02442396 · $0.3911
NRA-Levetiracetam · DIN 02499207 · $0.3911
PMS-Levetiracetam · DIN 02296128 · $0.3911
Riva-Levetiracetam · DIN 02482282 · $0.3911
Sandoz Levetiracetam · DIN 02461994 · $0.3911
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02247028
Shortage record checked October 6, 2026
Levetiracetam · DIN 02353350 · 500 mg · tablet
Limited Use, Reason for Use code 473 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 473 required
Write on scriptReason for Use code 473 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 473
Reason for Use code 473
As adjunctive therapy in the treatment of seizure disorders where control by other listed anticonvulsants has been unsatisfactory.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Levetiracetam · DIN 02353350
Manufacturer: Sanis Health Inc.; listing date 2011-08-04
Health Canada: Marketed since 2023-07-04 · brand LEVETIRACETAM · ATC N03AX14 LEVETIRACETAM · form Tablet · route Oral · ingredients LEVETIRACETAM 500 MG · company Sanis health inc · schedule Prescription
Levetiracetam: Formulary list price $0.39 per unit (the source does not state the unit; exact figure $0.3911). What the ministry pays, not the patient.
Ministry pays: $0.3911 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02353350: Levetiracetam
Raw flags: sec12=Y, sec3=Y
Item: 281200092; group id 434; item number 1084; lccId 00266; manufacturer id SAI
Source form: Tab; strength: 500mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.3911; ministry $0.3911
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02353350
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83855Interchangeable products
Ach-Levetiracetam · DIN 02399784 · $0.3911
Act Levetiracetam · DIN 02274191 · $0.3911
Apo-Levetiracetam · DIN 02285932 · $0.3911
Auro-Levetiracetam · DIN 02375257 · $0.3911
Jamp Levetiracetam Tablets · DIN 02504561 · $0.3911
Jamp-Levetiracetam · DIN 02403021 · $0.3911
Keppra · DIN 02247028 · $0.3911
Levetiracetam · DIN 02442558 · $0.3911
M-Levetiracetam · DIN 02524570 · $0.3911
Mint-Levetiracetam · DIN 02442396 · $0.3911
NRA-Levetiracetam · DIN 02499207 · $0.3911
PMS-Levetiracetam · DIN 02296128 · $0.3911
Riva-Levetiracetam · DIN 02482282 · $0.3911
Sandoz Levetiracetam · DIN 02461994 · $0.3911
Shortage status: resolved shortage (ended April 10, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02353350
Shortage record checked October 6, 2026
Levetiracetam · DIN 02442558 · 500 mg · tablet
Limited Use, Reason for Use code 473 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 473 required
Write on scriptReason for Use code 473 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 473
Reason for Use code 473
As adjunctive therapy in the treatment of seizure disorders where control by other listed anticonvulsants has been unsatisfactory.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Levetiracetam · DIN 02442558
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-08-28
Health Canada: Marketed since 2018-04-13 · brand LEVETIRACETAM · ATC N03AX14 LEVETIRACETAM · form Tablet · route Oral · ingredients LEVETIRACETAM 500 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Levetiracetam: Formulary list price $0.39 per unit (the source does not state the unit; exact figure $0.3911). What the ministry pays, not the patient.
Ministry pays: $0.3911 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02442558: Levetiracetam
Raw flags: sec12=Y, sec3=Y
Item: 281200092; group id 434; item number 1084; lccId 00266; manufacturer id SIV
Source form: Tab; strength: 500mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.3911; ministry $0.3911
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02442558
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92689Interchangeable products
Ach-Levetiracetam · DIN 02399784 · $0.3911
Act Levetiracetam · DIN 02274191 · $0.3911
Apo-Levetiracetam · DIN 02285932 · $0.3911
Auro-Levetiracetam · DIN 02375257 · $0.3911
Jamp Levetiracetam Tablets · DIN 02504561 · $0.3911
Jamp-Levetiracetam · DIN 02403021 · $0.3911
Keppra · DIN 02247028 · $0.3911
Levetiracetam · DIN 02353350 · $0.3911
M-Levetiracetam · DIN 02524570 · $0.3911
Mint-Levetiracetam · DIN 02442396 · $0.3911
NRA-Levetiracetam · DIN 02499207 · $0.3911
PMS-Levetiracetam · DIN 02296128 · $0.3911
Riva-Levetiracetam · DIN 02482282 · $0.3911
Sandoz Levetiracetam · DIN 02461994 · $0.3911
Shortage status: resolved shortage (ended April 27, 2018); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02442558
Shortage record checked October 6, 2026
Mint-Levetiracetam · DIN 02442396 · 500 mg · tablet
Limited Use, Reason for Use code 473 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 473 required
Write on scriptReason for Use code 473 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 473
Reason for Use code 473
As adjunctive therapy in the treatment of seizure disorders where control by other listed anticonvulsants has been unsatisfactory.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mint-Levetiracetam · DIN 02442396
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2021-11-30
Health Canada: Marketed since 2021-06-28 · brand MINT-LEVETIRACETAM · ATC N03AX14 LEVETIRACETAM · form Tablet · route Oral · ingredients LEVETIRACETAM 500 MG · company Mint pharmaceuticals inc · schedule Prescription
Mint-Levetiracetam: Formulary list price $0.39 per unit (the source does not state the unit; exact figure $0.3911). What the ministry pays, not the patient.
Ministry pays: $0.3911 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02442396: Mint-Levetiracetam
Raw flags: sec12=Y, sec3=Y
Item: 281200092; group id 434; item number 1084; lccId 00266; manufacturer id MIN
Source form: Tab; strength: 500mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.3911; ministry $0.3911
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02442396
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92675Interchangeable products
Ach-Levetiracetam · DIN 02399784 · $0.3911
Act Levetiracetam · DIN 02274191 · $0.3911
Apo-Levetiracetam · DIN 02285932 · $0.3911
Auro-Levetiracetam · DIN 02375257 · $0.3911
Jamp Levetiracetam Tablets · DIN 02504561 · $0.3911
Jamp-Levetiracetam · DIN 02403021 · $0.3911
Keppra · DIN 02247028 · $0.3911
Levetiracetam · DIN 02353350 · $0.3911
Levetiracetam · DIN 02442558 · $0.3911
M-Levetiracetam · DIN 02524570 · $0.3911
NRA-Levetiracetam · DIN 02499207 · $0.3911
PMS-Levetiracetam · DIN 02296128 · $0.3911
Riva-Levetiracetam · DIN 02482282 · $0.3911
Sandoz Levetiracetam · DIN 02461994 · $0.3911
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02442396
Shortage record checked October 6, 2026
PMS-Levetiracetam · DIN 02296128 · 500 mg · tablet
Limited Use, Reason for Use code 473 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 473 required
Write on scriptReason for Use code 473 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 473
Reason for Use code 473
As adjunctive therapy in the treatment of seizure disorders where control by other listed anticonvulsants has been unsatisfactory.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Levetiracetam · DIN 02296128
Manufacturer: Pharmascience Inc.; listing date 2007-11-10
Health Canada: Marketed since 2021-09-30 · brand PMS-LEVETIRACETAM · ATC N03AX14 LEVETIRACETAM · form Tablet · route Oral · ingredients LEVETIRACETAM 500 MG · company Pharmascience inc · schedule Prescription
PMS-Levetiracetam: Formulary list price $0.39 per unit (the source does not state the unit; exact figure $0.3911). What the ministry pays, not the patient.
Ministry pays: $0.3911 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02296128: PMS-Levetiracetam
Raw flags: sec12=Y, sec3=Y
Item: 281200092; group id 434; item number 1084; lccId 00266; manufacturer id PMS
Source form: Tab; strength: 500mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.3911; ministry $0.3911
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02296128
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78146Interchangeable products
Ach-Levetiracetam · DIN 02399784 · $0.3911
Act Levetiracetam · DIN 02274191 · $0.3911
Apo-Levetiracetam · DIN 02285932 · $0.3911
Auro-Levetiracetam · DIN 02375257 · $0.3911
Jamp Levetiracetam Tablets · DIN 02504561 · $0.3911
Jamp-Levetiracetam · DIN 02403021 · $0.3911
Keppra · DIN 02247028 · $0.3911
Levetiracetam · DIN 02353350 · $0.3911
Levetiracetam · DIN 02442558 · $0.3911
M-Levetiracetam · DIN 02524570 · $0.3911
Mint-Levetiracetam · DIN 02442396 · $0.3911
NRA-Levetiracetam · DIN 02499207 · $0.3911
Riva-Levetiracetam · DIN 02482282 · $0.3911
Sandoz Levetiracetam · DIN 02461994 · $0.3911
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02296128
Shortage record checked October 6, 2026
Sandoz Levetiracetam · DIN 02461994 · 500 mg · tablet
Limited Use, Reason for Use code 473 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 473 required
Write on scriptReason for Use code 473 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 473
Reason for Use code 473
As adjunctive therapy in the treatment of seizure disorders where control by other listed anticonvulsants has been unsatisfactory.
Coverage limit:
LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Levetiracetam · DIN 02461994
Manufacturer: Sandoz Canada Inc.; listing date 2017-09-28
Health Canada: Marketed since 2017-08-04 · brand SANDOZ LEVETIRACETAM · ATC N03AX14 LEVETIRACETAM · form Tablet · route Oral · ingredients LEVETIRACETAM 500 MG · company Sandoz canada incorporated · schedule Prescription
Sandoz Levetiracetam: Formulary list price $0.39 per unit (the source does not state the unit; exact figure $0.3911). What the ministry pays, not the patient.
Ministry pays: $0.3911 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02461994: Sandoz Levetiracetam
Raw flags: sec12=Y, sec3=Y
Item: 281200092; group id 434; item number 1084; lccId 00266; manufacturer id SDZ
Source form: Tab; strength: 500mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.3911; ministry $0.3911
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02461994
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94974Interchangeable products
Ach-Levetiracetam · DIN 02399784 · $0.3911
Act Levetiracetam · DIN 02274191 · $0.3911
Apo-Levetiracetam · DIN 02285932 · $0.3911
Auro-Levetiracetam · DIN 02375257 · $0.3911
Jamp Levetiracetam Tablets · DIN 02504561 · $0.3911
Jamp-Levetiracetam · DIN 02403021 · $0.3911
Keppra · DIN 02247028 · $0.3911
Levetiracetam · DIN 02353350 · $0.3911
Levetiracetam · DIN 02442558 · $0.3911
M-Levetiracetam · DIN 02524570 · $0.3911
Mint-Levetiracetam · DIN 02442396 · $0.3911
NRA-Levetiracetam · DIN 02499207 · $0.3911
PMS-Levetiracetam · DIN 02296128 · $0.3911
Riva-Levetiracetam · DIN 02482282 · $0.3911
Shortage status: resolved shortage (ended June 27, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02461994
Shortage record checked October 6, 2026
Other products in the same Health Canada class (N03AX): coverage varies; not interchangeable
Lamotrigine (Lamictal): general benefit
Topiramate (Topamax Sprinkle): general benefit, limited Use 321, not a benefit
Brivaracetam (Brivlera): limited Use 548
Cenobamate (Xcopri): limited Use 719
Lacosamide (Vimpat): limited Use 430
Perampanel (Fycompa): limited Use 430, 564
14 more in the class list below
Other drugs in the same formulary class (28:12 Anticonvulsants) and how they are covered
Matched class: 28:12 Anticonvulsants
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: CLONAZEPAM, DIVALPROEX SODIUM, ETHOSUXIMIDE, VALPROATE SODIUM
Some products covered without a code (check the product listing): CARBAMAZEPINE, GABAPENTIN, LAMOTRIGINE, PHENYTOIN (DIPHENYLHYDANTOIN), PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM, PREGABALIN, PRIMIDONE, TOPIRAMATE, VALPROIC ACID
28:12 Anticonvulsants
· 28 products · General benefit (25), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (3) · strengths: 25mg, 100mg, 150mg · Tab
· 4 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (2), General benefit (2) · strengths: 6mg/mL, 25mg/mL, 50mg · O/L, Tab
1 INDICATIONS
KEPPRA (levetiracetam) is indicated as adjunctive therapy in the management of adult (> 18 years of
age) patients with epilepsy who are not satisfactorily controlled by conventional therapy.
1.1 Pediatrics
Pediatrics (< 18 years of age): Based on the data submitted and reviewed by Health Canada, the safety
and efficacy of KEPPRA in pediatric patients has not been established; therefore, Health Canada has not
authorized an indication for pediatric use (see 7.1.3 Pediatrics and 10.3 Pharmacokinetics, Special
Populations and Conditions, Pediatrics).
1.2 Geriatrics
Geriatrics (≥ 65 years of age): Evidence from clinical studies and experience suggests that use in the
geriatric population is associated with differences in safety or efficacy (see 7.1.4 Geriatrics,
4.2 Recommended Dose and Dosage Adjustment, Geriatrics and 10.3 Pharmacokinetics, Special
Populations and Conditions, Geriatrics).
https://pdf.hres.ca/dpd_pm/00069867.PDF
PM date: January 21, 2003
Source product: KEPPRA; DIN 02247027; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.